Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Video
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedman, J.
Right arrow Articles by MacCollin, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedman, J.
Right arrow Articles by MacCollin, M.
Related Collections
Right arrow All Movement Disorders
Right arrow Other hypersomnias
Right arrowRelated Article
NEUROLOGY 2006;67:2032-2035
© 2006 American Academy of Neurology
Brief Communications

Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency

Jennifer Friedman, MD, Keith Hyland, PhD, Nenad Blau, PhD and Mia MacCollin, MD

From the Department of Neurology (J.F., M.M.), Massachusetts General Hospital, Boston; Department of Neurology (J.F.), Rady Children’s Hospital–San Diego, CA; Horizon Molecular Medicine (K.H.), Atlanta, GA; and Division of Clinical Chemistry and Biochemistry (N.B.), University Children’s Hospital, Zurich, Switzerland.

Address correspondence and reprint requests to Dr. J. Friedman, Department of Neurology, Rady Children’s Hospital–San Diego, 8010 Frost St., San Diego, CA 92123; e-mail: jrfriedman{at}chsd.org

Sepiapterin reductase deficiency (SRD) is a rare, treatable disorder of monoamine metabolism with cognitive delay and l-dopa responsive movement disorder. We describe a patient with SRD and distinctive phenotypic feature of marked hypersomnolence. Our patient showed improvement with therapies directed at both serotonergic and dopaminergic deficiencies. This case illustrates symptoms that characterize the SRD phenotype and demonstrates the importance of systematic treatment trials addressing the various biochemical abnormalities present.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the December 12 issue to find the title link for this article.

Supported in part by the Swiss National Science Foundation grant no. 310000-107500/1 (to N.B.).

Disclosure: The authors report no conflicts of interest.

Received May 15, 2006. Accepted in final form September 13, 2006.


Related Article

December 12 Highlights
Neurology 2006 67: 1908-1909. [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.